Following Roche’s community letter announcing the discontinuation of GENERATION HD2, and EHDN’s Executive Committee statement, we welcomed David Hawellek, Biomarker & Experimental Medicine Leader at Roche, who presented the results and key learnings from the Phase 2 clinical trial testing tominersen in Huntington’s disease, on behalf of Peter McColgan, Global Development Leader.

📅Date: Tuesday, 29 September 2026

 

EHDN Chair Patrick Weydt and Deputy Chair Åsa Petersén hosted the meeting. The event also featured an expert panel discussion followed by a Q&A session.

The recording is available below and on EHDN YouTube.